Dr Reddys launches Supanac
Dr Reddys Laboratories Ltd has announced that the Company has launched Supanacr (Diclofenac potassium immediate release 50 mg tablets) in India, increasing its offering in the Rs 2700 crores (~ $688 million) NSAID market. (Source: IMS ORG June MAT ‘07).
Supanac r is in-licensed from Applied Pharma Research (APR), Switzerland and is used for Acute Pain management. This patented product has been developed by Dynamic Buffered Technology (DBT) making it a superior formulation of Diclofenac, which reaches peak plasma concentration approximately four times faster than Diclofenac enteric coated preparations thereby ensuring faster pain relief.